Kosmiadi G A, Abramova Z P, Vaneeva T V, Fomina N M, Gergert V Ia, Shmelev E I
Probl Tuberk. 1996(4):51-3.
The paper presents the first results of using cyclosporin A (CsA) to treat lymphocytes during their extracorporeal immunomodulation (EIL) in patient with fibrotic alveolitis of various etiology. Two-hour lymphocytic incubation in the medium containing 0.1-10 micrograms per ml of CsA was sufficient for CsA to show its in vitro immunosuppressive effect, which resulted in a substantial inhibition of a proliferative lymphocytic response to mitogens and antigens. Administration of CsA-treated lymphocytes induced no profound structural changes in lymphocytic subpopulations (CD3, CD4, CD8), but it was followed by a reduction in the baseline high proliferative lymphocytic response to PHA. The clinical effect, alveolitis alleviation was noted in all patients. It is suggested that clinical effects may be produced by a local concentration of the treated lymphocytes and their transferred CsA as well.
本文介绍了在各种病因所致纤维化肺泡炎患者的淋巴细胞体外免疫调节（EIL）过程中，使用环孢素A（CsA）治疗淋巴细胞的首批结果。在含有每毫升0.1 - 10微克CsA的培养基中对淋巴细胞进行两小时孵育，足以使CsA发挥其体外免疫抑制作用，这导致对有丝分裂原和抗原的淋巴细胞增殖反应受到显著抑制。给予经CsA处理的淋巴细胞并未引起淋巴细胞亚群（CD3、CD4、CD8）的深刻结构变化，但随后对PHA的基线高增殖淋巴细胞反应有所降低。所有患者均出现了肺泡炎缓解这一临床效果。提示临床效果可能是由经处理的淋巴细胞及其所携带的CsA的局部浓度产生的。
